Search

Your search keyword '"DAAR, ABDALLAH"' showing total 23 results
Start Over Author "DAAR, ABDALLAH" Publisher elsevier
23 results on '"DAAR, ABDALLAH"'

1. Contributors

Author

Allen, Richard D.M., primary, Barry, John M., additional, Basu, Amit, additional, Becker, Bryan N., additional, Billiau, A.D., additional, Bordea, Cristina, additional, Bradley, J. Andrew, additional, Brook, Nicholas R., additional, Campbell, Michael, additional, Chapman, Jeremy R., additional, Colvin, Robert B., additional, Cosimi, A. Benedict, additional, Cranston, David, additional, Daar, Abdallah S., additional, Dallman, Margaret J., additional, Davis, John A., additional, Delmonico, Francis L., additional, Dyar, Oliver J., additional, Ettenger, Robert B., additional, Fishman, Jay A., additional, Ford, Andria L., additional, Franc-Guimond, Julie, additional, Franklin, Patricia M., additional, Fuggle, Susan V., additional, Gloor, James M., additional, González, Ricardo, additional, Gruessner, Angelika C., additional, Gruessner, Rainer W.G., additional, Hamilton, David, additional, Israni, Ajay K., additional, Kahan, Barry D., additional, Kasiske, Bertram L., additional, Kirk, Allan D., additional, Knechtle, Stuart J., additional, Knight, Simon R., additional, Ko, Dicken S.C., additional, Kobayashi, Takashi, additional, Lally, Aoife, additional, Lee, Jin-Moo, additional, Leuvenink, Henri G.D., additional, Lucey, Michael R., additional, Mathieu, C., additional, Mauiyyedi, Shamila, additional, Mohacsi, Paula J., additional, Montgomery, Robert A., additional, Moosa, M. Rafique, additional, Morris, Peter J., additional, Nadig, Satish N., additional, Nankivell, Brian J., additional, Nanovic, Lisa, additional, Nicholson, Michael L., additional, Pirenne, J., additional, Pirsch, John D., additional, Ploeg, Rutger J., additional, Rianthavorn, Pornpimol, additional, Russell, Neil K.I., additional, Safdar, Nasia, additional, Said, Adnan, additional, Sarwal, Minnie M., additional, Sear, John W., additional, Shapiro, Ron, additional, Shoskes, Daniel, additional, Simpkins, Christopher E., additional, Sprangers, B., additional, Stegall, Mark D., additional, Sutherland, David E.R., additional, Taylor, Craig J., additional, Thompson, John F., additional, van Etten, E., additional, Venning, Vanessa, additional, Vo, Katie D., additional, Waer, Mark, additional, Warnecke, Gregor, additional, Watson, Christopher J.E., additional, Wells, Jennifer T., additional, Wojnarowska, Fenella, additional, Wood, Kathryn J., additional, Wood, Kenneth E., additional, and Wright, Linda, additional

Published
2008
Full Text
View/download PDF

3. SCIONA LTD.: A PIONEER IN NUTRIGENOMICS: THE PATH TO CONSUMER ACCEPTANCE11This case study was written by Cécile M. Bensimon under the supervision of Peter Singer, following interviews they conducted with Sciona executives and ethics consultants in November 2002. We would like to acknowledge Martin Tierney's work on the study, and Abdallah Daar, Margaret Eaton and David Finegold provided constructive comments and edits on earlier drafts. This case study is one in a series produced under a grant by The Seaver Institute and Genome Canada to study models for ensuring ethical decision making in bioscience firms. Unless otherwise specified, all attributed quotes were obtained during the case study interviews. We would like to thank all who participated in the case study, especially Rosalynn Gill-Garrison, whose invaluable assistance enabled us to complete this study.

Author

Finegold, David L., primary, Bensimon, Cécile M., additional, Daar, Abdallah S., additional, Eaton, Margaret L., additional, Godard, Béatrice, additional, Knoppers, Bartha Maria, additional, Mackie, Jocelyn E., additional, and Singer, Peter A., additional

Published
2005
Full Text
View/download PDF

4. PIPELINE BIOTECH A/S: COMPETING REGULATORY REGIMES FOR LABORATORY ANIMAL EXPERIMENTS11This case study was written by David Finegold based on interviews he conducted with Pipeline employees and a company consultant. Interviews were conducted by phone or at the Keck Graduate Institute in Claremont, California in April to June 2004. Unless otherwise specified, all quotations were obtained during these interviews. This case study is one in a series produced under grants funded by The Seaver Institute and Genome Canada to study models for ensuring ethical decision making in bioscience firms. Grateful appreciation is extended to all those who participated and assisted in this case study, especially to Rasmus Nelund, without whose efforts this case study could not have been written.

Author

Finegold, David L., primary, Bensimon, Cécile M., additional, Daar, Abdallah S., additional, Eaton, Margaret L., additional, Godard, Béatrice, additional, Knoppers, Bartha Maria, additional, Mackie, Jocelyn E., additional, and Singer, Peter A., additional

Published
2005
Full Text
View/download PDF

5. MERCK: STAYING THE COURSE11The case study was written by David Finegold based on interviews he conducted with Margaret Eaton and Jocelyn E. Mackie at Merck on March 30-31, 2004 at company headquarters in Whitehouse Station, NJ and Merck's Research Laboratories in Rahway, NJ. Unless otherwise specified, all quotes attributed to these people were obtained during interviews. This case study is one in a series produced under grants funded by The Seaver Institute and Genome Canada to study models for ensuring ethical decision making in bioscience firms. Everyone's participation, suggestions, and assistance are greatly appreciated. Special thanks are extended to Samir Khalil for arranging the visit.

Author

Finegold, David L., primary, Bensimon, Cécile M., additional, Daar, Abdallah S., additional, Eaton, Margaret L., additional, Godard, Béatrice, additional, Knoppers, Bartha Maria, additional, Mackie, Jocelyn E., additional, and Singer, Peter A., additional

Published
2005
Full Text
View/download PDF

6. PHARMASNPS INC.: CREATING AN ETHICS ADVISORY BOARD11This case study is of a real company that has been anonymized because the firm was acquired after the case was completed. The case study was written by Cécile M. Bensimon and David Finegold based on interviews they conducted on September 26, 2002 at Company headquarters. Four members of the company's EAB were also interviewed by phone. Unless otherwise specified, all quotes attributed to these people were obtained during interviews. This case study is one in a series produced under grants funded by The Seaver Institute and Genome Canada to study models for ensuring ethical decision making in bioscience firms. The participation, suggestions, and assistance of all involved are greatly appreciated.

Author

Finegold, David L., primary, Bensimon, Cécile M., additional, Daar, Abdallah S., additional, Eaton, Margaret L., additional, Godard, Béatrice, additional, Knoppers, Bartha Maria, additional, Mackie, Jocelyn E., additional, and Singer, Peter A., additional

Published
2005
Full Text
View/download PDF

7. TGN BIOTECH: A START-UP WITH ETHICAL ROOTS11This case was written by Jocelyn E. Mackie under the supervision of Abdallah S. Daar and with the assistance of Cécile M. Bensimon. All information, unless otherwise stated, was gathered from personal interviews of employees at TGN Biotech in August 2003 conducted by Mackie, Daar, and Bensimon. This case study is one in a series produced under grants funded by The Seaver Institute and Genome Canada to study models for ensuring ethical decision making in bioscience firms. Grateful appreciation is extended to all who participated and assisted in this case study, without whose efforts this case study could not have been written.

Author

Finegold, David L., primary, Bensimon, Cécile M., additional, Daar, Abdallah S., additional, Eaton, Margaret L., additional, Godard, Béatrice, additional, Knoppers, Bartha Maria, additional, Mackie, Jocelyn E., additional, and Singer, Peter A., additional

Published
2005
Full Text
View/download PDF

8. DIVERSA INC.: ETHICAL ISSUES IN BIOPROSPECTING PARTNERSHIPS11The case study was written by Cécile M. Bensimon and David Finegold based on interviews they conducted with Béatrice Godard between February 2003 and November 2004. This case study is one in a series produced under grants funded by The Seaver Institute and Genome Canada to study models for ensuring ethical decision making in bioscience firms. Grateful appreciation is extended to all those who participated and assisted in this case study. Special thanks are extended to Leif Christoffersen for invaluable his assistance in this case.

Author

Finegold, David L., primary, Bensimon, Cécile M., additional, Daar, Abdallah S., additional, Eaton, Margaret L., additional, Godard, Béatrice, additional, Knoppers, Bartha Maria, additional, Mackie, Jocelyn E., additional, and Singer, Peter A., additional

Published
2005
Full Text
View/download PDF

9. MAXIM PHARMACEUTICALS (A): INTERNAL AND EXTERNAL DIALOGUES11This case study was written by David Finegold based on interviews he conducted with employees and a company consultant. Interviews were conducted with Beatrice Godard at Maxim and by phone in April 2003. Unless otherwise specified, all quotes were obtained during these interviews. This case study is one in a series produced under grants funded by The Seaver Institute and Genome Canada to study models for ensuring ethical decision making in bioscience firms. Grateful appreciation is extended to all those who participated and assisted in this case study, especially to Larry Stambaugh, without whose efforts this case study could not have been written.

Author

Finegold, David L., primary, Bensimon, Cécile M., additional, Daar, Abdallah S., additional, Eaton, Margaret L., additional, Godard, Béatrice, additional, Knoppers, Bartha Maria, additional, Mackie, Jocelyn E., additional, and Singer, Peter A., additional

Published
2005
Full Text
View/download PDF

10. INTERLEUKIN GENETICS AND ALTICOR: AN UNLIKELY PARTNERSHIP11This case study was written by David Finegold based on interviews conducted on October 1, 2003 at Interleukin in Waltham, Massachusetts. Unless otherwise specified, all quotations that appear in the case were obtained during these interviews. Interviews were conducted by Finegold, Jocelyn Mackie, and Cécile M. Bensimon. This case study is one in a series produced under grants funded by The Seaver Institute and Genome Canada to study models for ensuring ethical decision making in bioscience firms. We would especially like to thank Rahul Dhanda without whose help this case study would not have been possible.

Author

Finegold, David L., primary, Bensimon, Cécile M., additional, Daar, Abdallah S., additional, Eaton, Margaret L., additional, Godard, Béatrice, additional, Knoppers, Bartha Maria, additional, Mackie, Jocelyn E., additional, and Singer, Peter A., additional

Published
2005
Full Text
View/download PDF

11. MILLENNIUM PHARMACEUTICALS, INC.: CREATING AND SUSTAINING CORPORATE VALUES11The case study was written by Margaret L. Eaton based on interviews with 10 Millennium employees on September 25, 2002 at company headquarters. Interviews were conducted with David Finegold, who also gave valuable editing assistance. Rahul Dhanda provided important insights and Emily Taylor collected and provided helpful background materials. This case study is one in a series produced under a grant funded by The Seaver Institute and Genome Canada to study models of informed ethical decision making in bioscience firms. Grateful appreciation is extended to all those who participated and assisted, especially to Millennium's Gary Cohen, without whose efforts this case study could not have been written.

Author

Finegold, David L., primary, Bensimon, Cécile M., additional, Daar, Abdallah S., additional, Eaton, Margaret L., additional, Godard, Béatrice, additional, Knoppers, Bartha Maria, additional, Mackie, Jocelyn E., additional, and Singer, Peter A., additional

Published
2005
Full Text
View/download PDF

12. GENZYME: PUTTING PATIENTS FIRST11This case study was written by David Finegold and Jocelyn Mackie based on interviews conducted at Genzyme on September 30 and October 1, 2003 at Genzyme's headquarters in Cambridge, Massachusetts. Unless otherwise specified, all quotes in the case were obtained during interviews. Interviews were conducted by Finegold, Mackie and Cæcile Bensimon. This case study is one in a series produced under grants funded by The Seaver Institute and Genome Canada to study models for ensuring ethical decision making in bioscience firms. We would like to thank all those who partcipated in this study, especially Elliott Hillback for his help in arranging the case study and detailed feedback on the earlier drafts of the study.

Author

Finegold, David L., primary, Bensimon, Cécile M., additional, Daar, Abdallah S., additional, Eaton, Margaret L., additional, Godard, Béatrice, additional, Knoppers, Bartha Maria, additional, Mackie, Jocelyn E., additional, and Singer, Peter A., additional

Published
2005
Full Text
View/download PDF

13. CONCLUSION: LESSONS FOR COMPANIES AND FUTURE ISSUES

Author

Finegold, David L., primary, Bensimon, Cécile M., additional, Daar, Abdallah S., additional, Eaton, Margaret L., additional, Godard, Béatrice, additional, Knoppers, Bartha Maria, additional, Mackie, Jocelyn E., additional, and Singer, Peter A., additional

Published
2005
Full Text
View/download PDF

14. RESEARCH TEAM

Author

Finegold, David L., primary, Bensimon, Cécile M., additional, Daar, Abdallah S., additional, Eaton, Margaret L., additional, Godard, Béatrice, additional, Knoppers, Bartha Maria, additional, Mackie, Jocelyn E., additional, and Singer, Peter A., additional

Published
2005
Full Text
View/download PDF

15. NOVO NORDISK: THE TRIPLE BOTTOM LINE11This case study was written by Jocelyn E. Mackie under the supervision of Abdallah S. Daar. All data for this case come from interviews performed by Daar and Mackie on March 15–17, 2004, at Novo Nordisk, unless otherwise noted. This case is one in a series produced under grants funded by The Seaver Institute and Genome Canada to study models for ensuring ethical decision making in bioscience firms. We would like to thank all the employees of Novo Nordisk who took part in this study.

Author

Finegold, David L., primary, Bensimon, Cécile M., additional, Daar, Abdallah S., additional, Eaton, Margaret L., additional, Godard, Béatrice, additional, Knoppers, Bartha Maria, additional, Mackie, Jocelyn E., additional, and Singer, Peter A., additional

Published
2005
Full Text
View/download PDF

16. INTRODUCTION

Author

Finegold, David L., primary, Bensimon, Cécile M., additional, Daar, Abdallah S., additional, Eaton, Margaret L., additional, Godard, Béatrice, additional, Knoppers, Bartha Maria, additional, Mackie, Jocelyn E., additional, and Singer, Peter A., additional

Published
2005
Full Text
View/download PDF

17. AFFYMETRIX, INC.: USING CORPORATE ETHICS ADVICE11This case study was written by Margaret L. Eaton based on interviews with three Affymetrix employees and five ethics advisors in July and August 2003. Two of the interviews were conducted with David Finegold, who also gave valuable assistance in editing this case study, as did Abdallah Daar. This case study is one in a series produced under grants funded by The Seaver Institute and Genome Canada to study models for ensuring informed ethical decision making in bioscience firms. Grateful appreciation is extended to all those who participated and assisted, especially to Affymetrix's Katie Tillman Buck, without whose efforts this case study could not have been written.

Author

Finegold, David L., primary, Bensimon, Cécile M., additional, Daar, Abdallah S., additional, Eaton, Margaret L., additional, Godard, Béatrice, additional, Knoppers, Bartha Maria, additional, Mackie, Jocelyn E., additional, and Singer, Peter A., additional

Published
2005
Full Text
View/download PDF

18. MONSANTO COMPANY: BIO-AGRICULTURE PIONEER11The case study was written by Cécile M. Bensimon under the supervision of Peter Singer, following interviews they conducted with Monsanto executives in December 2002 at company headquarters in St. Louis, Mo. Abdallah Daar, Margaret Eaton and David Finegold, provided constructive comments and edits on earlier drafts. This case study is one in a series produced under grants funded by The Seaver Institute and Genome Canada to study models for ensuring ethical decision making in bioscience firms. Unless otherwise specified, all attributed quotes were obtained during the case study interviews. We would like to thank all the Monsanto executives who participated in the case, especially Gerard Barry, whose invaluable assistance enabled us to complete this study.

Author

Finegold, David L., primary, Bensimon, Cécile M., additional, Daar, Abdallah S., additional, Eaton, Margaret L., additional, Godard, Béatrice, additional, Knoppers, Bartha Maria, additional, Mackie, Jocelyn E., additional, and Singer, Peter A., additional

Published
2005
Full Text
View/download PDF

20. Refugees in the eastern Mediterranean region.

Author

Aljouni K, Al-Mazrou YY, Ammar WS, Daar AS, Daulaire N, Ezzati M, Fathalla M, Houssin DP, Kickbusch I, Mechbal A, Rashad HM, and Sabri B

Subjects
Altruism, Humans, Mediterranean Region ethnology, World Health Organization, Health Services Needs and Demand organization & administration, Refugees
Published
2015
Full Text
View/download PDF

21. Incentives for organ donation: proposed standards for an internationally acceptable system.

Author

Matas AJ, Satel S, Munn S, Richards JR, Tan-Alora A, Ambagtsheer FJ, Asis MD, Baloloy L, Cole E, Crippin J, Cronin D, Daar AS, Eason J, Fine R, Florman S, Freeman R, Fung J, Gaertner W, Gaston R, Ghahramani N, Ghods A, Goodwin M, Gutmann T, Hakim N, Hippen B, Huilgol A, Kam I, Lamban A, Land W, Langnas A, Lesaca R, Levy G, Liquette R, Marks WH, Miller C, Ona E, Pamugas G, Paraiso A, Peters TG, Price D, Randhawa G, Reed A, Rigg K, Serrano D, Sollinger H, Sundar S, Teperman L, van Dijk G, Weimar W, and Danguilan R

Subjects
Humans, Motivation, Principle-Based Ethics, Tissue Donors ethics, Tissue and Organ Procurement ethics
Abstract

Incentives for organ donation, currently prohibited in most countries, may increase donation and save lives. Discussion of incentives has focused on two areas: (1) whether or not there are ethical principles that justify the current prohibition and (2) whether incentives would do more good than harm. We herein address the second concern and propose for discussion standards and guidelines for an acceptable system of incentives for donation. We believe that if systems based on these guidelines were developed, harms would be no greater than those to today's conventional donors. Ultimately, until there are trials of incentives, the question of benefits and harms cannot be satisfactorily answered., (© 2011 The American Society of Transplantation and the American Society of Transplant Surgeons.)

Published
2012
Full Text
View/download PDF

22. The roles of a bioethicist on an organ transplantation service.

Author

Wright L, Ross K, and Daar AS

Subjects
Humans, Living Donors, Ethicists, Organ Transplantation ethics, Tissue and Organ Procurement ethics
Abstract

Organ transplantation centers have expanded and increased in the last 20 years as transplant recipient outcomes have improved steadily and transplantation has moved from experimentation to treatment of choice for several indications. Transplantation presents difficult ethical and legal challenges for the transplant community and society. These include declarations of death, consent to donation and allocation of a scarce societal resource, i.e. transplantable organs. Policy and practice reflect the law, societal beliefs and prevailing values. A bioethicist contributes to a transplant team by clarifying values held by various stakeholders or embodied in decisions and policies, conducting clinical consultations, developing and interpreting policy and researching the ethics of innovations for rationing and increasing available supply of organs for transplantation. The bioethicist's interdisciplinary education, preparation, experience and familiarity with ethics, law, sociology and philosophy and skills of mediation, communication and ethical analysis contribute to addressing and resolving many issues in transplantation. This paper outlines the various roles of a bioethicist on a transplantation service, using case examples to illustrate some of the ethical issues.

Published
2005
Full Text
View/download PDF

23. Genomics--a global public good?

Author

Thorsteinsdóttir H, Daar AS, Smith RD, and Singer PA

Subjects
Genomics methods, Humans, Developing Countries, Genomics trends, Global Health, Human Genome Project organization & administration
Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results